Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00943826
Registration number
NCT00943826
Ethics application status
Date submitted
17/07/2009
Date registered
22/07/2009
Date last updated
25/09/2017
Titles & IDs
Public title
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Query!
Secondary ID [1]
0
0
2008-006146-26
Query!
Secondary ID [2]
0
0
BO21990
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Glioblastoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bevacizumab
Treatment: Drugs - Temozolomide
Treatment: Other - Radiation therapy
Treatment: Drugs - Placebo
Experimental: Bevacizumab + RT + Temozolomide - In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m\^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m\^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
Placebo comparator: Placebo + RT + Temozolomide - In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m\^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m\^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
Treatment: Drugs: Bevacizumab
10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
Treatment: Drugs: Temozolomide
75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
Treatment: Other: Radiation therapy
30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
Treatment: Drugs: Placebo
Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator
Query!
Assessment method [1]
0
0
PFS is defined as time from randomization to disease progression (PD) or death. PD was assessed using adapted Macdonald response criteria (modified World Health Organization \[WHO\] criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging \[MRI\] scans,neurological assessment and changes in corticosteroid use. PD is assessed as greater than or equal to(\>=) 25% increase in sum of products of the longest diameters of all index lesions (enhancing,measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing,non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment.
Query!
Timepoint [1]
0
0
Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
Query!
Primary outcome [2]
0
0
Co-Primary: Overall Survival (OS)
Query!
Assessment method [2]
0
0
Overall Survival was defined as the time from randomization to death due to any cause.
Query!
Timepoint [2]
0
0
Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
Query!
Secondary outcome [1]
0
0
PFS as Assessed by an Independent Review Facility
Query!
Assessment method [1]
0
0
An Independent Review Facility reviewed the MRI scans used by investigator to evaluate radiological tumor response. PFS is defined as time from randomization to PD or death. PD was assessed using adapted Macdonald response (modified WHO) criteria based on 3 components: radiological tumor assessments using MRI scans, neurological assessment and changes in corticosteroid use. PD is assessed as \>=25% increase in sum of products of the longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing, non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment.
Query!
Timepoint [1]
0
0
Randomization until PFS Event (Until data cutoff= 31 March 2012 [up to 29.5 months])
Query!
Secondary outcome [2]
0
0
Kaplan-Meier (KM) Estimate of One Year Overall Survival
Query!
Assessment method [2]
0
0
KM estimate of one year overall survival (probability to survive for at least 1 year) was reported. Corresponding 95% confidence interval (CI) was calculated using Greenwood's formula.
Query!
Timepoint [2]
0
0
Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
Query!
Secondary outcome [3]
0
0
Kaplan-Meier (KM) Estimate of Two Year Overall Survival
Query!
Assessment method [3]
0
0
KM estimate of two year overall survival was reported (probability to survive for at least 2 years). Corresponding 95% CI was calculated using Greenwood's formula.
Query!
Timepoint [3]
0
0
Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
Query!
Secondary outcome [4]
0
0
PFS in Participants With Stable/Improved Health Related Quality of Life (HRQoL) Based on European Organization for Research & Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30)(EORTC QLQ-C30) & EORTC QLQ Brain Neoplasm 20 (BN20)
Query!
Assessment method [4]
0
0
EORTC QLQ-C30: 30 items; 5 functional scales; 9 symptom scales; \& global health status. Most questions used 4-point scale (1:Not at all, 4:Very much), 2 questions used 7-point scale (1:very poor, 7:Excellent). EORTC QLQ-BN20: 20 items rated on a 4 point scale (1:not at all, 4:very much). EORTC QLQ-C30 and BN20 scores were transformed to a 0-100 scale, higher score=better functioning/global health (C30) or more severe symptoms (BN20). Stable HRQoL: change from baseline (BL) within 10 points. Improved HRQoL: an increase from BL \>/=10 points for functioning/global health status, \& decrease of \>/=10 points for symptoms. PFS is reported for participants with Stable/Improved global health; physical, social functioning (C30); motor dysfunction \& communication deficit (BN20). PFS: randomization to PD or death. PD: \>=25% increase in sum of products of longest diameters of index lesions; or progression of existing non-index lesions; or appearance of new lesions; or neurological worsening.
Query!
Timepoint [4]
0
0
Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
Query!
Secondary outcome [5]
0
0
Number of Participants With Non-Serious Adverse Events, Serious Adverse Events and Death
Query!
Assessment method [5]
0
0
An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as AE.A serious adverse event (SAE) is any experience that suggests a significant hazard,contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Non-serious adverse events (Non-SAEs) included all AEs except SAEs (non-SAEs = all AEs - SAEs). Nine participants randomized to the Placebo+RT+Temozolomide arm incorrectly received at least 1 dose of bevacizumab and were added to the Bevacizumab+RT+Temozolomide arm for Safety.
Query!
Timepoint [5]
0
0
Randomization until study completion (Until data cutoff= 09 Sep 2015 [up to 64 months])
Query!
Eligibility
Key inclusion criteria
Key
* newly diagnosed glioblastoma
* World Health Organization (WHO) performance status less than or equal to (<=2)
* stable or decreasing corticosteroid dose within 5 days prior to randomization
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* evidence of recent hemorrhage on postoperative magnetic resonance imaging (MRI) of brain
* any prior chemotherapy or immunotherapy for glioblastomas and low grade astrocytomas
* any prior radiotherapy to brain
* clinically significant cardiovascular disease
* history of greater than or equal to (>=) grade 2 hemoptysis within 1 month prior to randomization
* previous centralized screening for Methylguanine-DNA methyltransferase (MGMT) status for enrollment into a clinical trial
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/06/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/09/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
921
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Prince of Wales Hospital; Department of Medical Oncology - Randwick
Query!
Recruitment hospital [2]
0
0
North Shore Private Hospital; Northern Specialist Centre - St Leonards
Query!
Recruitment hospital [3]
0
0
Royal North Shore Hospital; Department of Medical Oncology - St Leonards
Query!
Recruitment hospital [4]
0
0
Princess AleXandra Hospital; Department of Medical Oncology - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Calvary North Adelaide; North Adeliade Oncology Centre - North Adelaide
Query!
Recruitment hospital [6]
0
0
Royal Melbourne Hospital; Hematology and Medical Oncology - Parkville
Query!
Recruitment hospital [7]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [6]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Virginia
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Bruxelles
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Edegem
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Gent
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Liège
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Roeselare
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Alberta
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
British Columbia
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Manitoba
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Saskatchewan
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Aalborg
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
København Ø
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Odense
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Bobigny
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bordeaux
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Bron
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Clermont Ferrand
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Clichy
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Dijon
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Marseille
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Montpellier
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Nancy
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Paris
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Dresden
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Gießen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Hamburg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Heidelberg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Ibbenbühren
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Mainz
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
München
Query!
Country [41]
0
0
Greece
Query!
State/province [41]
0
0
Heraklion
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Larissa
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Thessaloniki
Query!
Country [44]
0
0
Hong Kong
Query!
State/province [44]
0
0
Hong Kong
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Budapest
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Miskolc
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Pecs
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Haifa
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Jerusalem
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Petach Tikva
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Tel Hashomer
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Emilia-Romagna
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Lombardia
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Piemonte
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Umbria
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Veneto
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Hiroshima
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Ibaraki
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Kumamoto
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Osaka
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Saitama
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Tokyo
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Busan
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Daegu
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Goyang-si
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Jeollanam-do
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Seoul
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Amsterdam
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Eindhoven
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Utrecht
Query!
Country [71]
0
0
New Zealand
Query!
State/province [71]
0
0
Auckland
Query!
Country [72]
0
0
New Zealand
Query!
State/province [72]
0
0
Christchurch
Query!
Country [73]
0
0
New Zealand
Query!
State/province [73]
0
0
Hamilton
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Bialystok
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Bydgoszcz
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Lublin
Query!
Country [77]
0
0
Portugal
Query!
State/province [77]
0
0
Coimbra
Query!
Country [78]
0
0
Portugal
Query!
State/province [78]
0
0
Lisboa
Query!
Country [79]
0
0
Portugal
Query!
State/province [79]
0
0
Porto
Query!
Country [80]
0
0
Romania
Query!
State/province [80]
0
0
Bucharest
Query!
Country [81]
0
0
Romania
Query!
State/province [81]
0
0
Cluj-napoca
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Targu Mures
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
Moscow
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
St. Petersburg
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Barcelona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Madrid
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Malaga
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Valencia
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Göteborg
Query!
Country [90]
0
0
Sweden
Query!
State/province [90]
0
0
Lund
Query!
Country [91]
0
0
Sweden
Query!
State/province [91]
0
0
Umea
Query!
Country [92]
0
0
Sweden
Query!
State/province [92]
0
0
Uppsala
Query!
Country [93]
0
0
Switzerland
Query!
State/province [93]
0
0
Geneve
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Birmingham
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Bristol
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
London
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Newcastle Upon Tyne
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Nottingham
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Romford
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Sheffield
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Sutton
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of care alone. Participants were randomly assigned to either the bevacizumab (10 milligrams per kilogram (mg/kg) intravenously \[IV\] once every 2 week \[q2w\]) or the placebo arm, in combination with radiation therapy (total dose 60 Gray \[Gy\], administered as 2 Gy fractions, 5 days/week) plus temozolomide (75 milligrams per meter squared \[mg/m\^2\] oral administration \[po\] daily) for 6 weeks. After a 4 week treatment break, participants continued to receive bevacizumab (10 mg/kg IV q2w) or placebo, plus temozolomide (150-200 mg/m\^2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of maintenance treatment or until disease progression or unacceptable toxicity, whichever occured first. Following the maintenance phase, bevacizumab (15 mg/kg iv every 3 weeks \[q3w\]) or placebo monotherapy continued. The time on study treatment was until disease progression.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00943826
Query!
Trial related presentations / publications
Hagiwara A, Schlossman J, Shabani S, Raymond C, Tatekawa H, Abrey LE, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Cloughesy TF, Ellingson BM. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. J Neurooncol. 2022 Sep;159(3):509-518. doi: 10.1007/s11060-022-04088-3. Epub 2022 Jul 17. Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J, Romain S, Appay R, Graillon T, Mason W, Carpentier AF, Brandes AA, Ouafik L', Wick W, Baaziz A, Gigan JP, Arguello RJ, Figarella-Branger D, Chinot O, Tabouret E. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun. 2022 Jan 3;10(1):1. doi: 10.1186/s40478-021-01305-4. Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol. 2016 Sep;18(9):1313-8. doi: 10.1093/neuonc/now046. Epub 2016 Mar 22. Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro Oncol. 2016 Jul;18(7):991-1001. doi: 10.1093/neuonc/nov300. Epub 2016 Jan 24. Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. Epub 2015 May 26. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013 May;13(5):347. doi: 10.1007/s11910-013-0347-2.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00943826
Download to PDF